Cytek Biosciences to Participate in UBS and Stephens Investor Conferences
Cytek Biosciences will participate in investor conferences hosted by UBS and Stephens.
Related stories
US Midterms, Earnings and Jobs Report Set to Test AI-Wary Market
US midterm elections, a heavy slate of corporate earnings and the monthly jobs report will test stock investors next week after setbacks in the AI trade.
M impact | EQUITY | Oct 30, 2026, 10:00 AM UTC
Intel outlook raises new doubts about earnings recovery
A Street View report says Intel's outlook has raised new questions about its earnings recovery, citing weakness in the PC market, manufacturing problems and expansion costs.
M impact | EQUITY | Oct 30, 2026, 09:58 AM UTC
JPMorgan Downgrades First Industrial Realty Trust to Neutral, Sets $60 Target
JPMorgan cut its rating on First Industrial Realty Trust to Neutral from Overweight and set a $60 price target.
M impact | EQUITY | Oct 30, 2026, 09:56 AM UTC
AstraZeneca Reports Q3 Results Beat, Launches $1.5 Billion Annual Savings Plan
AstraZeneca shares rise after Q3 results beat; the company launched an annual savings plan worth $1.5 billion.
M impact | EQUITY | Oct 30, 2026, 09:56 AM UTC
AI Stock Selloff Deepens as Nasdaq Futures Fall More Than 2%
Nasdaq futures fell more than 2% after quarterly results from Intel and Amazon rocked confidence in artificial-intelligence stocks. Treasury yields fell to multiweek lows as invest
M impact | EQUITY | Oct 30, 2026, 09:55 AM UTC
JPMorgan Downgrades Coursera to Neutral, Sets $5 Price Target
JPMorgan downgraded Coursera to Neutral from Overweight and set a $5 price target.
M impact | EQUITY | Oct 30, 2026, 09:54 AM UTC